
Marianne Grønlie Guren
- Professor, Consultant; MD, PhD
Group leader Colorectal Oncology Research Group
Responsible for: Colorectal and Anal Cancer
Professsor II position at Institute of Clinical Medicine, UiO
Publications 2025
EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases
Cancer Treat Rev, 136, 102926 (in press)
DOI 10.1016/j.ctrv.2025.102926, PubMed 40179590
Evaluation of the psychometric properties of patient-reported outcome measures of health-related quality of life across the European cancer continuum: a systematic review protocol using COSMIN methodology
BMJ Open, 15 (3), e088716
DOI 10.1136/bmjopen-2024-088716, PubMed 40157731
Deep learning reconstruction for detection of liver lesions at standard-dose and reduced-dose abdominal CT
Eur Radiol (in press)
DOI 10.1007/s00330-025-11596-z, PubMed 40251443
Publications 2024
Diffusion-weighted magnetic resonance imaging as an early prognostic marker of chemoradiotherapy response in squamous cell carcinoma of the anus: An individual patient data meta-analysis
Phys Imaging Radiat Oncol, 31, 100618
DOI 10.1016/j.phro.2024.100618, PubMed 39188809
Survival prediction in patients with gynecological cancer irradiated for brain metastases
Acta Oncol, 63, 206-212
DOI 10.2340/1651-226X.2023.34899, PubMed 38647023
Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
Oncoimmunology, 13 (1), 2372886
DOI 10.1080/2162402X.2024.2372886, PubMed 38952672
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial
Br J Cancer, 130 (12), 1921-1928
DOI 10.1038/s41416-024-02696-6, PubMed 38664577
International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set
EClinicalMedicine, 78, 102939
DOI 10.1016/j.eclinm.2024.102939, PubMed 39720423
Patient-reported outcomes after treatment for rectal cancer-A prospective nationwide study
Colorectal Dis, 27 (1) (in press)
DOI 10.1111/codi.17231, PubMed 39515999
Revisiting the use of the EORTC QLQ-STO22 to assess health-related quality of life of patients with gastric cancer: incorporating updated treatment options and cross-cultural perspectives
Gastric Cancer, 27 (4), 722-734
DOI 10.1007/s10120-024-01492-8, PubMed 38668819
Ongoing prospective studies on reirradiation: A systematic review of a clinical trials database
Radiother Oncol, 202, 110624
DOI 10.1016/j.radonc.2024.110624, PubMed 39532233
Publications 2023
Stability of metabolic tumor volume may enable radiotherapy dose painting in anal cancer
Phys Med, 114, 103151
DOI 10.1016/j.ejmp.2023.103151, PubMed 37813051
Magnetic resonance imaging of anal cancer: tumor characteristics and early prediction of treatment outcome
Strahlenther Onkol, 200 (1), 19-27
DOI 10.1007/s00066-023-02114-5, PubMed 37429949
Nordic anal cancer (NOAC) group consensus guidelines for risk-adapted delineation of the elective clinical target volume in anal cancer
Acta Oncol, 62 (8), 897-906
DOI 10.1080/0284186X.2023.2240490, PubMed 37504978
A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers
Eur J Nucl Med Mol Imaging, 50 (13), 4010-4023
DOI 10.1007/s00259-023-06320-2, PubMed 37632562
Correction to: Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences
Gastric Cancer, 26 (1), 167
DOI 10.1007/s10120-022-01346-1, PubMed 36269499
Publications 2022
The survival gap between young and older patients after surgical resection for colorectal cancer remains largely based on early mortality: A EURECCA comparison of four European countries
J Geriatr Oncol, 13 (6), 803-812
DOI 10.1016/j.jgo.2022.04.011, PubMed 35527207
Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer - The RAPIDO trial
Radiother Oncol, 171, 69-76
DOI 10.1016/j.radonc.2022.04.013, PubMed 35447283
Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
Cancer Treat Res Commun, 31, 100517
DOI 10.1016/j.ctarc.2022.100517, PubMed 35114500
A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer
Cancers (Basel), 14 (7)
DOI 10.3390/cancers14071697, PubMed 35406469
Characteristics and fate of patients with rectal cancer not entering a curative-intent treatment pathway: A complete nationwide registry cohort of 3,304 patients
Eur J Surg Oncol, 48 (8), 1831-1839
DOI 10.1016/j.ejso.2022.04.013, PubMed 35527055
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
Br J Cancer, 127 (12), 2227-2233
DOI 10.1038/s41416-022-02004-0, PubMed 36229579
Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015-2016
BMC Cancer, 22 (1), 220
DOI 10.1186/s12885-022-09306-9, PubMed 35227226
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)
ESMO Open, 7 (4), 100529
DOI 10.1016/j.esmoop.2022.100529, PubMed 35816951
Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences
Gastric Cancer, 25 (4), 665-677
DOI 10.1007/s10120-022-01309-6, PubMed 35689705
"Global Multidisciplinary Team Meetings": Challenging Cases Virtual Forums from the International Multidisciplinary Anal Cancer Conference (IMACC)
Clin Colorectal Cancer, 21 (3), 175-187
DOI 10.1016/j.clcc.2022.02.006, PubMed 35346604
International Validation of the EORTC QLQ-ANL27, a Field Study to Test the Anal Cancer-Specific Health-Related Quality-of-Life Questionnaire
Int J Radiat Oncol Biol Phys, 115 (5), 1155-1164
DOI 10.1016/j.ijrobp.2022.11.002, PubMed 36402360
Development and validation of prognostic models for anal cancer outcomes using distributed learning: protocol for the international multi-centre atomCAT2 study
Diagn Progn Res, 6 (1), 14
DOI 10.1186/s41512-022-00128-8, PubMed 35922837
Publications 2021
One-year excess mortality and treatment in surgically treated patients with colorectal cancer: A EURECCA European comparison
Eur J Surg Oncol, 47 (7), 1651-1660
DOI 10.1016/j.ejso.2021.01.011, PubMed 33518367
E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models
Mol Oncol, 16 (12), 2312-2329
DOI 10.1002/1878-0261.13159, PubMed 34890102
Predicting outcomes in anal cancer patients using multi-centre data and distributed learning - A proof-of-concept study
Radiother Oncol, 159, 183-189
DOI 10.1016/j.radonc.2021.03.013, PubMed 33753156
Deep learning-based automatic delineation of anal cancer gross tumour volume: a multimodality comparison of CT, PET and MRI
Acta Oncol, 61 (1), 89-96
DOI 10.1080/0284186X.2021.1994645, PubMed 34783610
Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer
Clin Colorectal Cancer, 20 (4), 279-287
DOI 10.1016/j.clcc.2021.09.006, PubMed 34645589
Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
Cancer Epidemiol Biomarkers Prev, 31 (2), 342-351
DOI 10.1158/1055-9965.EPI-21-0555, PubMed 34853022
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
J Transl Med, 19 (1), 384
DOI 10.1186/s12967-021-03062-3, PubMed 34496878
De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity
Genome Med, 13 (1), 143
DOI 10.1186/s13073-021-00956-1, PubMed 34470666
Factors associated with emergency-onset diagnosis, time to treatment and type of treatment in colorectal cancer patients in Norway
BMC Cancer, 21 (1), 757
DOI 10.1186/s12885-021-08415-1, PubMed 34187404
Accurate population-based model for individual prediction of colon cancer recurrence
Acta Oncol, 60 (10), 1241-1249
DOI 10.1080/0284186X.2021.1953138, PubMed 34279175
Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study. (vol 148, 1575, 2021)
Int. J. Cancer, 149 (6), E9
DOI 10.1002/ijc.33717
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Ann Oncol, 32 (9), 1087-1100
DOI 10.1016/j.annonc.2021.06.015, PubMed 34175386
Characteristics of Early-Onset vs Late-Onset Colorectal Cancer: A Review
JAMA Surg, 156 (9), 865-874
DOI 10.1001/jamasurg.2021.2380, PubMed 34190968
Intensity modulated proton therapy planning study for organ at risk sparing in rectal cancer re-irradiation
Acta Oncol, 60 (11), 1436-1439
DOI 10.1080/0284186X.2021.1953139, PubMed 34264785
Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer
Acta Oncol, 60 (7), 921-930
DOI 10.1080/0284186X.2021.1918763, PubMed 33966592
Distinctions Between Self-Report and Performance-Based Measures of Physical Function in Older Patients Prior to Chemotherapy
Cancer Nurs, 44 (6), E735-E744
DOI 10.1097/NCC.0000000000000964, PubMed 34183518
Common and distinct characteristics associated with self-reported functional status in older patients with cancer receiving chemotherapy
Eur J Oncol Nurs, 54, 102033
DOI 10.1016/j.ejon.2021.102033, PubMed 34537538
Publications 2020
Re-irradiation for recurrent rectal cancer - a single-center experience
Acta Oncol, 59 (5), 534-540
DOI 10.1080/0284186X.2020.1725111, PubMed 32056476
Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project)
Gut, 70 (1), 114-126
DOI 10.1136/gutjnl-2020-320625, PubMed 32482683
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
Lancet Oncol, 22 (1), 29-42
DOI 10.1016/S1470-2045(20)30555-6, PubMed 33301740
Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer
ESMO Open, 5 (6), e001040
DOI 10.1136/esmoopen-2020-001040, PubMed 33219056
Treatment strategies and overall survival for incurable metastatic colorectal cancer - A EURECCA international comparison including 21,196 patients from the Netherlands and Norway
Eur J Surg Oncol, 46 (6), 1167-1173
DOI 10.1016/j.ejso.2020.02.005, PubMed 32151531
Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Clin Cancer Res, 26 (15), 4107-4119
DOI 10.1158/1078-0432.CCR-19-3637, PubMed 32299813
Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version
Acta Oncol, 59 (9), 1016-1023
DOI 10.1080/0284186X.2020.1778180, PubMed 32574087
Chemotherapy During Pregnancy for Advanced Colon Cancer: A Case Report
Clin Colorectal Cancer, 19 (2), 141-144
DOI 10.1016/j.clcc.2020.02.013, PubMed 32222353
Should calculation of chemotherapy dosage for bowel cancer be based on body composition?
Tidsskr Nor Laegeforen, 140 (8)
DOI 10.4045/tidsskr.19.0769, PubMed 32463187
International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic
Radiother Oncol, 148, 213-215
DOI 10.1016/j.radonc.2020.03.039, PubMed 32342861
Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study
Int J Cancer, 148 (7), 1575-1585
DOI 10.1002/ijc.33326, PubMed 33006395
International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct
J Clin Oncol, 38 (22), 2510-2518
DOI 10.1200/JCO.19.03266, PubMed 32530769
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity
EBioMedicine, 59, 102923
DOI 10.1016/j.ebiom.2020.102923, PubMed 32799124
Publications 2019
Changes in colorectal cancer incidence in seven high-income countries: a population-based study
Lancet Gastroenterol Hepatol, 4 (7), 511-518
DOI 10.1016/S2468-1253(19)30147-5, PubMed 31105047
Social networks for young patients with cancer: the time for system agility
Lancet Oncol, 20 (6), 765
DOI 10.1016/S1470-2045(19)30346-8, PubMed 31162090
Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases
Eur J Surg Oncol, 45 (12), 2340-2346
DOI 10.1016/j.ejso.2019.07.017, PubMed 31350075
High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases
Clin Colorectal Cancer, 19 (1), e26-e47
DOI 10.1016/j.clcc.2019.09.003, PubMed 31982351
The global challenge of colorectal cancer
Lancet Gastroenterol Hepatol, 4 (12), 894-895
DOI 10.1016/S2468-1253(19)30329-2, PubMed 31648973
Anal cancer chemoradiotherapy outcome prediction using 18F-fluorodeoxyglucose positron emission tomography and clinicopathological factors
Br J Radiol, 92 (1097), 20181006
DOI 10.1259/bjr.20181006, PubMed 30810343
High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy:A prospective longitudinal study
Eur J Oncol Nurs, 44, 101679
DOI 10.1016/j.ejon.2019.101679, PubMed 31751848
Symptoms during chemotherapy in colorectal cancer patients
Support Care Cancer, 27 (8), 3007-3017
DOI 10.1007/s00520-018-4598-y, PubMed 30607676
Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer
ESMO Open, 4 (3), e000523
DOI 10.1136/esmoopen-2019-000523, PubMed 31321083
Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer
Oncogenesis, 8 (6), 35
DOI 10.1038/s41389-019-0141-3, PubMed 31092812
Publications 2018
Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study
Lancet Oncol, 20 (1), 74-87
DOI 10.1016/S1470-2045(18)30646-6, PubMed 30545752
Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
Mol Oncol, 12 (9), 1639-1655
DOI 10.1002/1878-0261.12347, PubMed 29900672
Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison
Br J Cancer, 119 (4), 517-522
DOI 10.1038/s41416-018-0215-6, PubMed 30057408
Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016
Clin Colorectal Cancer, 18 (1), e96-e103
DOI 10.1016/j.clcc.2018.10.001, PubMed 30415990
CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer
Ann Oncol, 29 (5), 1227-1234
DOI 10.1093/annonc/mdy085, PubMed 29518181
Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison
Oncologist, 23 (8), 982-990
DOI 10.1634/theoncologist.2017-0551, PubMed 29567826
Publications 2017
Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence
Acta Oncol, 56 (3), 462-470
DOI 10.1080/0284186X.2016.1273546, PubMed 28077018
The normal tissue sparing potential of an adaptive plan selection strategy for re-irradiation of recurrent rectal cancer
Phys. Imag. Radiat. Oncol., 3, 43-48
DOI 10.1016/j.phro.2017.09.001
Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival
Colorectal Dis, 19 (8), 731-738
DOI 10.1111/codi.13622, PubMed 28181384
Target volume delineation of anal cancer based on magnetic resonance imaging or positron emission tomography
Radiat Oncol, 12 (1), 147
DOI 10.1186/s13014-017-0883-z, PubMed 28874205
Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer
Radiother Oncol, 126 (2), 222-228
DOI 10.1016/j.radonc.2017.11.018, PubMed 29217122
Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status
Eur J Cancer, 81, 26-35
DOI 10.1016/j.ejca.2017.04.026, PubMed 28595137
Preoperative chemoradiotherapy for rectal cancer and impact on outcomes - A population-based study
Radiother Oncol, 123 (3), 446-453
DOI 10.1016/j.radonc.2017.04.012, PubMed 28483302
Publications 2016
Palliative pelvic radiotherapy for symptomatic rectal cancer - a prospective multicenter study
Acta Oncol, 55 (12), 1400-1407
DOI 10.1080/0284186X.2016.1191666, PubMed 27332723
Two countries - Two treatment strategies for rectal cancer
Radiother Oncol, 121 (3), 357-363
DOI 10.1016/j.radonc.2016.11.010, PubMed 27887734
No Differences in Symptom Burden Between Colorectal Cancer Patients Receiving Curative Versus Palliative Chemotherapy
J Pain Symptom Manage, 52 (4), 539-547
DOI 10.1016/j.jpainsymman.2016.04.008, PubMed 27470003
Publications 2015
Palliative pelvic radiotherapy for symptomatic incurable prostate cancer – A prospective multicenter study
Radiother Oncol, 115 (3), 314-20
DOI 10.1016/j.radonc.2015.05.021, PubMed 26091575
Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010
Acta Oncol, 54 (10), 1714-22
DOI 10.3109/0284186X.2015.1034876, PubMed 25924970
Radiofrequency ablation of unresectable colorectal liver metastases: trends in management and outcome during a decade at a single center
Acta Radiol Open, 4 (7), 2058460115580877
DOI 10.1177/2058460115580877, PubMed 26346740
Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer
Eur J Cancer, 51 (18), 2740-6
DOI 10.1016/j.ejca.2015.08.029, PubMed 26597443
Is England closing the international gap in cancer survival?
Br J Cancer, 113 (5), 848-60
DOI 10.1038/bjc.2015.265, PubMed 26241817
Publications 2014
Reirradiation of locally recurrent rectal cancer: a systematic review
Radiother Oncol, 113 (2), 151-7
DOI 10.1016/j.radonc.2014.11.021, PubMed 25613395
Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines
Radiother Oncol, 113 (3), 352-8
DOI 10.1016/j.radonc.2014.10.002, PubMed 25499203
Publications 2013
Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors
Acta Oncol, 52 (4), 736-44
DOI 10.3109/0284186X.2013.770599, PubMed 23438358
Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort
Radiother Oncol, 108 (1), 55-60
DOI 10.1016/j.radonc.2013.05.037, PubMed 23891095
Target Volume Definition in Rectal Cancer: What Is the Best Imaging Modality?
Curr. Colorectal Cancer Rep., 9 (2), 116-125
DOI 10.1007/s11888-013-0170-9
Palliative pelvic radiotherapy of symptomatic incurable prostate cancer - a systematic review
Radiother Oncol, 110 (1), 55-60
DOI 10.1016/j.radonc.2013.08.008, PubMed 24044801
Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review
Acta Oncol, 53 (2), 164-73
DOI 10.3109/0284186X.2013.837582, PubMed 24195692
Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?
Clin Cancer Res, 19 (24), 6669-77
DOI 10.1158/1078-0432.CCR-13-1769, PubMed 24166914
Publications 2012
Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review
Acta Oncol, 52 (4), 679-90
DOI 10.3109/0284186X.2012.731521, PubMed 23190360
Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort
Int J Radiat Oncol Biol Phys, 83 (2), e173-80
DOI 10.1016/j.ijrobp.2011.12.062, PubMed 22436791
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study
Ann Oncol, 24 (1), 152-60
DOI 10.1093/annonc/mds276, PubMed 22967994
Publications 2010
Sexual function in females after radiotherapy for rectal cancer
Acta Oncol, 49 (6), 826-32
DOI 10.3109/0284186X.2010.486411, PubMed 20615170
[How do Norwegian oncologists perceive their working conditions?]
Tidsskr Nor Laegeforen, 130 (5), 487-9
DOI 10.4045/tidsskr.08.0305, PubMed 20224615
Publications 2009
Sexual function in males after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 76 (4), 1012-7
DOI 10.1016/j.ijrobp.2009.03.075, PubMed 19880263
Late side effects and quality of life after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 76 (4), 1005-11
DOI 10.1016/j.ijrobp.2009.03.010, PubMed 19540058
Publications 2008
Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH
Int J Radiat Oncol Biol Phys, 70 (3), 722-7
DOI 10.1016/j.ijrobp.2007.10.043, PubMed 18262088
Publications 2006
Dietary intake and nutritional indicators are transiently compromised during radiotherapy for rectal cancer
Eur J Clin Nutr, 60 (1), 113-9
DOI 10.1038/sj.ejcn.1602274, PubMed 16205744
Publications 2005
Rectal cancer - quality of life and side effects associated with radiotherapy and surgery
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 262, 1 b. (flere pag.)
BIBSYS 050522833, ISBN 82-8072-190-8
Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer
Eur J Surg Oncol, 31 (7), 735-42
DOI 10.1016/j.ejso.2005.05.004, PubMed 16180267
Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?
Histopathology, 47 (6), 560-4
DOI 10.1111/j.1365-2559.2005.02252.x, PubMed 16324192
Publications 2004
Biochemical signs of impaired cobalamin status during and after radiotherapy for rectal cancer
Int J Radiat Oncol Biol Phys, 60 (3), 807-13
DOI 10.1016/j.ijrobp.2004.04.018, PubMed 15465197
Publications 2003
Radiation therapy induced changes in male sex hormone levels in rectal cancer patients
Radiother Oncol, 68 (3), 249-53
DOI 10.1016/s0167-8140(03)00120-8, PubMed 13129632
Quality of life during radiotherapy for rectal cancer
Eur J Cancer, 39 (5), 587-94
DOI 10.1016/s0959-8049(02)00741-4, PubMed 12628837
Publications 2001
Quality of life in patients with urinary diversion after operation for locally advanced rectal cancer
Eur J Surg Oncol, 27 (7), 645-51
DOI 10.1053/ejso.2001.1195, PubMed 11669593